Tissue factor – Factor VIIa complex (TF-FVIIa)

The Tissue factor – Factor VIIa (TF-FVIIa) complex, also known as the extrinsic tenase, is the primary physiological initiator of the blood coagulation cascade. It forms when transmembrane Tissue Factor (TF) is exposed to the blood following vascular injury and binds to circulating Factor VIIa, creating a potent enzymatic complex that activates Factors IX and X (StatPearls: Physiology, Coagulation Cascade [3]). This activation leads to a 'thrombin burst,' which is essential for the conversion of fibrinogen to fibrin and the formation of a stable blood clot. In patients with hemophilia who have developed inhibitors against Factor VIII or IX, the intrinsic pathway is compromised, making the TF-FVIIa-mediated pathway and its downstream components critical for hemostasis. FEIBA (Factor Eight Inhibitor Bypassing Activity) is a therapeutic agent that utilizes this system by providing a mixture of factors that bypass the blocked steps of the cascade to generate thrombin directly (Shapiro et al., 2019 [4]). Modulating the TF-FVIIa complex is a key strategy in treating both bleeding disorders and pathological thrombosis, as it sits at the apex of the coagulation response.

Other names

Extrinsic tenase complexFactor III-Factor VIIa complexThromboplastin-Factor VIIa complexCD142-F7a complex

FEIBA acts as a bypassing agent by providing a concentrated mixture of vitamin K-dependent clotting factors (Factors II, IX, and X mainly as zymogens, and Factor VII mainly in activated form) that work in conjunction with the TF-FVIIa complex to promote thrombin generation, bypassing the need for Factors VIII or IX in the intrinsic pathway (FDA Label: FEIBA [1]; Turecek et al., 2004 [2]).